**Post-COVID**, viral seasonality has become **less predictable**, with **continuous surges** in **respiratory viral infections** over the last **2-3 years**.
**Current data** from **India and globally** suggests that **no new virus is posing a major threat**. However, **Respiratory Syncytial Virus (RSV)** has gained **significant attention** due to rising hospitalization rates.
**RSV (Respiratory Syncytial Virus)** is typically a **mild winter virus**, causing **cold-like symptoms**.
**Unlike COVID-19 or Influenza**, RSV usually does **not** lead to severe **morbidity or mortality** in adults, but it **can cause bronchiolitis in children**.
**Recent trends, however, indicate:**
**Unlike Influenza**, RSV **does not have regular antiviral treatments**. However, in **severely ill & immunocompromised patients**, the following options are available:
**Early detection is critical** since treatments vary across different **viral pneumonias**.
**A new RSV vaccine is currently available in the US** and is expected to be **introduced in India soon**.
**Widespread vaccination** could help reduce the impact of RSV, especially in **high-risk groups**.
Get connected with us on social networks!